Nottinghamshire COPD and Asthma Guidelines

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

Nottinghamshire COPD and Asthma Guidelines Dr Esther Gladman GP Prescribing Lead, Medicines Management Nottingham City CCG Feb 2012.
Improving Inhaler Technique through Community Pharmacy Service Greater Manchester Area Team January 2015.
Planning, COPD Hot Topics and CSA preparation Ruth Gooch 11/1/12.
SYMPTOM CONTROL FOR ADVANCED RESPIRATORY DISEASE
Clinical Knowledge Summaries CKS Chronic obstructive pulmonary disease (COPD) Diagnosis of COPD in primary care Educational slides based on the CKS topic.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE Treatment Opportunities in a Heartsink Disease Jim Reid.
Managing acute exacerbations of COPD in primary care.
Asthma Diagnosis Prescribing Acute Management Tracey Bradshaw Respiratory Consultant RIE.
Managing end stage COPD in primary care
COPD Alison Boland StR Respiratory medicine. Aims & Objectives Overview of COPD Recap basic knowledge Update on COPD Know when to use nebulisers and home.
Chronic obstructive pulmonary disease (COPD) Professor Bill MacNee
COPD GUIDELINES Sarah Cowdell. WHY GUIDELINES MATTER Predicted to be the third leading cause of death by 2030 Cause of over 30,000 deaths in the UK yearly.
1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Karen Homan NHS Bedfordshire
Matt Wong + Sheila Murphy Dec 13 th  AKT MINI EXAM  NICE – COPD GUIDELINES  BTS ASTHMA GUIDELINES  INHALER TECHNIQUE  QOF  SPIROMETRY  CSA.
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
Respiratory Service Framework Asthma and COPD Care (Nursing) Project Learning and Development Strategy.
Respiratory COPD/Asthma.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11 بسم الله الرحمن الرحیم با سلام.
Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
COPD Diagnosis & Management Anil Ramineni Specialist Respiratory Physiotherapist Community Respiratory Team.
Chronic Obstructive Pulmonary Disease Austin Paul K.
Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.
Responsible Respiratory Prescribing
P RACTICAL ISSUES IN L ONG T REM M ANAGEMENT OF A STHMA DESPITE REGULAR FOLLOW UP Dr kondekar Santosh TN Medical college Mumbai
Severe breathlessness
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
History Taking Zinc code: UKACL1878ea Date of preparation May 2015 AstraZeneca provided funding & reviewed for technical accuracy.
Asthma Guidelines, Diagnosis and Management Alison Hughes Respiratory Specialist Nurse Solent NHS Trust.
Berkshire West CCG TIPs 28th January 2015
Wendy Pigg Practice support Pharmacist/Independent Prescriber
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
Attaran D, Mashhad university of medical sciences.
Definition Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and a range of pathological changes in the lung.
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
PULMONARY REHABILITATION.
Clinical Knowledge Summaries CKS Chronic obstructive pulmonary disease (COPD) Diagnosis of COPD in primary care Educational slides based on the CKS topic.
Asthma and COPD Some highlights. How the lungs work 2.
GOLD 2017 major revision: Summary of key changes
Current management of COPD and when to refer?
Respiratory Initiatives: GOLD - ABCD, CAT Scores and myCOPD
COPD 2003.
Chronic Obstructive Pulmonary Disease(COPD)
Medicines Optimisation
COPD – Primary Care Update
Jessica Case study.
Managing acute exacerbations of COPD in primary care.
Research where it is most needed National Respiratory Strategy
COPD PATHWAY AND PRESCRIBING POLICY IN LAMA options (stop SAMA):
Asthma and chronic obstructive pulmonary disease (copd)
COPD Report 5 Coles Lane, Oakington, Cambridge, CB24 3BA.
Medicines Management – COPD update for LPC Jyoti Saini Hema Patel
COPD By Alaina Darby.
Monitoring asthma in primary care
COPD Dr MAMATHA SARTHI GPST3.
Gold standard COPD care
Medicines Optimisation
The Modern Management of Asthma: Getting it right Part 2
‘Moving in the right direction’
20 minute update Asthma and COPD
Management of Chronic Stable COPD
Gestione clinica della BPCO
Chronic Obstructive Pulmonary Disease
Prescribing Update - Respiratory July 2019
Integration of community pharmacy with PCNs
Introduction Project At Crown Street Surgery:
Presentation transcript:

Nottinghamshire COPD and Asthma Guidelines Dr Esther Gladman GP Prescribing Lead, Medicines Management Nottingham City CCG Feb 2012 Introduce self Documents – who & why Has anyone read COPD NICE? 350+! Suck eggs/bacsics Are you seeing a lot of COPD/asthma/HF What is difference?

Where to find & other resources Google: Nottinghamshire Area Prescribing Committee Medicines Traffic Light Classification List Shared Care Protocols Clinical Guidelines Formularies Policies and Prescribing Position Statements E-healthscope www.patient.co.uk www.prodigy.nhs.uk (was CKS)

e.g. from prodigy : What simple measures can I advise to manage breathlessness for people with end-stage COPD? Advise the person on the following simple measures to manage breathlessness. Sitting in front of a fan or open window (or using a hand-held fan). Positioning For example, advise the person to sit or stand leaning forward (for example onto a table or the back of a chair) and supporting their weight with their arms and upper body. Pursed-lip breathing Advise the person to inhale through the nose and then exhale slowly, for 4–6 seconds, through pursed lips. Other simple measures, not specific to chronic obstructive pulmonary disease (COPD) but recommended in the section on Simple measures to help dyspnoea in the PRODIGY topic on Palliative cancer care - dyspnoea, may be useful for people with COPD.

Nottinghamshire COPD Guideline Key points Most effective interventions Be aware other conditions Effective/cost effective prescribing Steroid dose, pneumonia & adverse Be aware side effects and adverse effects of meds Where can you make a difference?

Most Effective Interventions 1. Stopping smoking is the only treatment that slows the progression of COPD and is the most cost effective treatment in COPD. NNT 5 –to prevent death at age 70 Motivational questioning, cost cigs & inhalers, Allen Carr, anxiety, dopamine,worsening of symptoms, dementia

Most Effective Interventions: 2. Pulmonary Rehabilitation MRC dyspnoea score 3, 4, 5 or recent admission “more breathless than contemporaries when walking or gets breathless on exertion & needs to rest” NNT 2 to improve exercise tolerance by a clinically useful amount NNT 4 to stop readmission over 6/12 if given early after an exacerbation

Most Effective Interventions 3. Self Management Plans NNT 10 to reduce admission in low risk patients NNT 3 to reduce admission in high risk patients (1 previous admission or LTOT or previous use of Prednisolone) NNT 5 for patient held “emergency supply pack” (prednisolone +/- antibiotic) to reduce admission

Beware diagnosis >40 years old Smoker or ex-smoker, non-smoking spouse of smoker or dusty occupation Spirometry FEV1 < 80% predicted and post bronchodilator FEV1/FVC ratio < 70% and typical symptoms NB FEV1 – an increase of >400ml after bronchodilator suggests asthma not COPD Consider CXR/FBC, ECG for alternative diagnoses or red flag symptoms such as haemoptysis

Be aware: are symptoms in accord with severity of COPD? FEV1 Rapid decline? e.g. >200ml in 3 years, exacerbations/Excess sputum Re-assess for co-morbidity, treatment adherence, inhaler technique Consider bronchiectasis check sputum for unusual organisms/Acid & Alcohol Fast bacilli ? Ca CXR,FBC,ECG NB 25 % will have IHD/ cardiac failure

Consider stepping down/swopping Explanation of flow chart Look at flow chart in conjunction with Stop smoking Optimise inhaler technique (e.g. spacers with MDIs) and review regularly Consider stopping new treatment if patient feels no improvement (4 weeks) longer may be needed for a reduction in exacerbations Consider stepping down/swopping There is no combination MDI licensed for COPD if patient preference: Fostair 100/6 (2 puffs BD £29.32) or Seretide 125 + spacer (2puffs BD, £35) can be considered, which gives similar ICS dose to Accuhaler 500. NB Seretide 250 MDI is not recommended High dose ICS (fluticasone 1000 microgram) increase the risk of pneumonia NNH=47 LABA vs LAMA – there is no significant difference re: reduction in exacerbation or hospitalisation rates. Use tiotropium Spiriva Handihaler® (18 mcg/day) not Spiriva Respimat® (mist device) All patients must be advised not to exceed the maximum daily dose

Effective/cost effective prescribing Stop smoking Optimise inhaler technique (e.g. spacers with MDIs) Consider stopping new treatment if patient feels no improvement (4 weeks) longer may be needed for a reduction in exacerbations Consider stepping down/swopping Look at flow chart in conjunction with Stop smoking Optimise inhaler technique (e.g. spacers with MDIs) and review regularly Consider stopping new treatment if patient feels no improvement (4 weeks) longer may be needed for a reduction in exacerbations Consider stepping down/swopping

Effective/cost effective prescribing LABA vs LAMA – there is no significant difference re: reduction in exacerbation or hospitalisation rates.

Effective/cost effective prescribing There is no combination MDI licensed for COPD However if patient preference: Fostair 100/6 (2 puffs BD £29.32) or Seretide 125 + spacer (2puffs BD, £35) can be considered, which gives similar ICS dose to Accuhaler 500. NB Seretide 250 MDI is not recommended

Adverse effects of steroid High dose ICS (ie fluticasone 1000 mcg = Seretide 250) increases the risk of pneumonia, NNH = 47 ie. Beware those with frequent exacerbations Other steroid effects - Diab/thrush/cataracts Osteoporosis prophylaxis for patients having 4 courses of oral steroid within 12 months

Be aware side effects and adverse effects of meds Use tiotropium Spiriva Handihaler® (18 mcg/day) not Spiriva Respimat® (mist device) All patients must be advised not to exceed the maximum daily dose All anticholinergics have some cardiovascular effect Fometerol and beta agonists also have effect

NBs Mucolytic only if troublesome phlegm: carbocisteine 750mg TDS (£24.60) can be trialled for 4 weeks. Stop if no effect. Drop to maintenance dose: 750mg BD if effective. Consider using in winter months only. Mucolytics do not prevent exacerbations Consider theophylline 3rd line: Uniphyllin 200mg BD (£2.94) care with elderly & concomitant medications see BNF. Theophylline levels? NNT=33

NBs 25% will have co-morbidity e.g. IHD/cardiac failure. Beta blockers can be used in COPD Dose of emergency supply pack?

Actions Flu & pneumococcal vaccination Inhaler use/Medication /step Stop smoking advice /refer New Leaf Patient info/empowerment MRC dyspnoea score 3, 4 or 5/functional disability refer for pulmonary rehabilitation Self management plan and anticipatory prescription pack Weight/diet/exercise. Little & often leaflets

Oxygen Sat ≤92% - refer to chest clinic /oxygen assessment service Palliative Care Planning If end-stage COPD/cor pulmonale

Nottinghamshire Adult Asthma Treatment Summary Micro break & shake Break & shake

Nottinghamshire Asthma Guideline Key points Step up and down Use LABA and ICS in a combination inhaler Be aware of inhaler equivalent steroid doses Step 3a is addition of LABA not increase ICS too Twitchiness of asthma Same steroid risks as for COPD Pros & cons of SMART Theophylline levels/interactions

Step Consider stepping up if: Consider stepping down if : 1. Using SABA 3 times a week or more 2. Symptoms 3 or > times x week 3. An exacerbation in the last 2 years 4. Waking due to symptoms one night a week Ensure adherence and inhaler technique Consider stepping down if : Asthma control has been good for 3 months on current therapy N.B. Steroid dose reductions should be slow as patients deteriorate at different rates. Reduce by 25-50% & monitor

Appropriate spacer/ Other devices? Peak flow meter?

Step 3a nb add LABA only

Step 3b & c

Step 3 alternative

SMART Pros: opener & reliever, inc dose steroid when need it Cons: device, symptoms, side effects

Step 4 asthma nb this is where use of Seretide 250 MDI is appropriate

nb Oral steroid - sometimes higher dose & shorter course than COPD Same steroid risks as for COPD Written Self-Management Plan/lifestyle/house dust mite/patient beliefs/info Co-morbidity

Key points summary Step up and down Always give LABA and ICS in combination inhaler (unlike COPD) Step 3a is addition of LABA not increase ICS too Be aware potency of ICS Inhaler and equivalent steroid doses